

Nivolumab + ipilimumab CheckMate-9LA

### PRELIMINARY SCORE

**CURATIVE**



**NON-CURATIVE**



### ADJUSTMENTS

**Quality of life**



Not qualified for an ESMO-MCBS credit



**Serious and disabling adverse effects**



**Other adjustments**



Nivolumab + ipilimumab CheckMate-9LA

### SCORE

**CURATIVE**



Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response



Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Tumour type: Thoracic Malignancies

Therapeutic Indication: First line treatment of mNSCLC with no sensitising EGFR mutation or ALK translocation

Experimental Arm: Nivolumab + ipilimumab + 2 cycles of platinum-based ChT

Control Arm: Chemotherapy

